Skip to content

Effect of Preoperative Intrathecal Dexamethasone Versus Dexmedetomidine on Paralytic Ileus After Major Abdominal Surgery

Effect of Preoperative Intrathecal Dexamethasone Versus Dexmedetomidine on Paralytic Ileus After Major Abdominal Surgery

Status
Not yet recruiting
Phases
Phase 4
Study type
Interventional
Source
ClinicalTrials.gov
Registry ID
NCT06752317
Enrollment
60
Registered
2024-12-30
Start date
2025-01-01
Completion date
2026-03-01
Last updated
2024-12-30

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Paralytic Ileus

Keywords

major abdominal surgery

Brief summary

Postoperative Ileus (POI) is considered as intolerance of oral intake due to disruption of the normal coordinated propulsive motor activity of the gastrointestinal (GI) tract following abdominal or non-abdominal surgery. Dexamethasone & Dexmedetomidine have been reported to attenuate the incidence of paralytic ileus after abdominal surgeries. Previous study has shown that a single dose of DM before induction of anesthesia may be beneficial to reduce ileus for IBD by alleviating the postoperative systemic inflammatory response. Perioperative dexmedetomidine in major abdominal surgeries significantly decreased the time to flatus, defecation, and resuming normal diet, shortened length of stay, and improved haemodynamic stability. The aim of this study is to compare the effect of preoperative intrathecal dexamethasone versus dexmedetomidine on paralytic ileus after major abdominal surgery.

Detailed description

Postoperative Ileus (POI) is considered as intolerance of oral intake due to disruption of the normal coordinated propulsive motor activity of the gastrointestinal (GI) tract following abdominal or non-abdominal surgery. Dexamethasone & Dexmedetomidine have been reported to attenuate the incidence of paralytic ileus after abdominal surgeries. Previous study has shown that a single dose of DM before induction of anesthesia may be beneficial to reduce ileus for IBD by alleviating the postoperative systemic inflammatory response. Perioperative dexmedetomidine in major abdominal surgeries significantly decreased the time to flatus, defecation, and resuming normal diet, shortened length of stay, and improved haemodynamic stability.

Interventions

DRUGDexamethasone

patients will receive intrathecal dexamethasone 8 mg in 3 ml volume.

DRUGDexmedetomidine

patients will receive intrathecal dexmedetomidine 0.5 µg/kg in 3 ml volume.

Sponsors

Assiut University
Lead SponsorOTHER

Study design

Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
TREATMENT
Masking
QUADRUPLE (Subject, Caregiver, Investigator, Outcomes Assessor)

Eligibility

Sex/Gender
ALL
Age
18 Years to 60 Years
Healthy volunteers
No

Inclusion criteria

* • Age: 18-60 years. * Sex: both males and females. * ASA physical status: I and II. * Operation: Open major abdominal surgery. * The surgery has to involve gastrointestinal resection and/or anastomosis.

Exclusion criteria

* • History of abnormal bowl habit or bowel obstruction * Allergy to dexamethasone or dexmedetomidine * Electrolyte disturbance * Patient who receive any drugs known to influence gastrointestinal motility. * Mental disorders or inability to cooperate * Morbid obesity (BMI \> 40), pregnancy, lactation * Diabetes * After neoadjuvant chemotherapy. * History of use of any steroids within the last 3 months * Previous abdominal surgery, herniorrhaphy or unplanned secondary surgery

Design outcomes

Primary

MeasureTime frameDescription
Incidence of postoperative vomiting24 hoursnumber of participants who had experienced vomiting on day 1.

Contacts

Primary ContactAbdelrahman Mohamed Hamed, resident doctor
AbdElrahman.16266086@med.aun.edu.eg+201149919109

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026